Yan Sun

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 950 citations

Oncology, Phase 2B/3, Afatinib Versus Placebo +9

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 591 citations · Full text

Impaired angiogenesis in aminopeptidase N-null mice

Roberto Rangel, Yan Sun, Liliana Guzman‐Rojas et al. · Proceedings of the National Academy of Sciences · 2007 · 125 citations · Full text

Inflammation, Aminopeptidase N, Angiogenesis +14

Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including <i>VEGFA</i>, in human osteosarcoma

Jilong Yang, Da Yang, Yan Sun et al. · Cancer · 2011 · 120 citations · Full text

IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Song Gao, Yan Sun, Xuebin Zhang et al. · Cancer Research · 2016 · 106 citations · Full text